Takeda moves to dismiss 'abandoned' US antitrust claims in Amitiza case
MLex Summary: Takeda Pharmaceuticals has moved to dismiss "abandoned" statutory monopolization and unfair and deceptive acts and practices claims brought by end payor plaintiffs, who allege the company illegally delayed generic...To view the full article, register now.
Already a subscriber? Click here to view full article